Literature DB >> 16122495

Evaluation of the enclose proximal anastomosis device in coronary artery bypass grafting.

Sary F Aranki1, Prem S Shekar, Afshin Ehsan, Margaretta Byrne-Taft, Gregory S Couper.   

Abstract

PURPOSE: Minimal manipulation of the ascending aorta during coronary artery bypass grafting may reduce the incidence of adverse perioperative events related to atheroembolic events. The objective of this study was to evaluate a new proximal anastomotic device (Novare Enclose device [Novare Surgical Systems, Cupertino, CA]). DESCRIPTION: Over a 23-month period, a total of 76 proximal anastomoses were performed in 50 patients (40 males and 10 females; mean age, 74.36 years). In 45 patients, the proximal anastomosis was constructed before the distal (25 off-pump and 20 on-pump), and in 5 patients the proximal anastomosis was constructed on cardiopulmonary bypass because of diseased ascending aortas. EVALUATION: The average time per anastomosis was <8 minutes. There were no device related complications. There were no atheroembolic complications in this cohort of patients. One patient underwent cardiac catheterization postoperatively, and the proximal vein anastomosis in this patient was widely patent.
CONCLUSIONS: The Novare Enclose proximal anastomotic device (Novare Surgical Systems) appears to be safe and effective as a tool for proximal anastomosis within a reasonable time period and is comparable with accepted techniques.

Entities:  

Mesh:

Year:  2005        PMID: 16122495     DOI: 10.1016/j.athoracsur.2004.10.043

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  The Use of Enclose(®)II Anastomosis Assist Device for the Proximal Coronary Branch Anastomosis to Vascular Graft.

Authors:  Keita Kikuchi; Keiichi Tambara; Taira Yamamoto; Motoshige Yamasaki; Hitoshi Hirose; Atsushi Amano
Journal:  Ann Vasc Dis       Date:  2010-07-21

2.  New device for saphenous vein-to-aorta proximal anastomosis without side-clamping.

Authors:  Ernesto Tappainer
Journal:  J Cardiothorac Surg       Date:  2007-05-04       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.